Blue cone monochromatism (BCM) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction syndrome, caused by mutations in the OPN1LW/OPN1MW gene cluster on the X chromosome. The cluster contains a single OPN1LW and one or more copies of the OPN1MW gene and controls the expression of the red (L, long wavelength) and green (M, middle wavelength) cone photoreceptor opsins. The genes expressing the opsin for the third cone subtype, S (short-wavelength) or blue cones (OPN1SW), and the rod pigment are autosomal and not affected in BCM. Consequently, vision in affected males is subserved only by S cone and rod function, as no functional L or M cones are present in the retina while Tritan discrimination, which has been reported to deteriorate with increasing illuminance and scotopic perception are retained.
The
prevalence of Blue cone monochromatism (BCM) varies between 1 to 1.75 cases per
100,000 population. Colour discrimination is severely impaired from birth and
BCM patients typically present reduced visual acuity (6/24 to 6/60), pendular
nystagmus, photophobia, and often have a myopic pattern.
The competitive
landscape of Blue cone monochromatism (BCM) includes country-specific approved
and pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Blue
cone monochromatism (BCM) across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Blue
cone monochromatism (BCM) Market
Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 ADVM-062 Adverum
Biotechnologies, Inc. -
Comments
Post a Comment